Latest news with #Imfinzi
Yahoo
02-06-2025
- Business
- Yahoo
AstraZeneca Highlights Significant Gains Across Three Major Cancer Trials At ASCO
AstraZeneca Plc (NASDAQ:AZN) on Monday released results from three Phase 3 clinical trials at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting: DESTINY-Breast09, MATTERHORN, and SERENA-6. In the DESTINY-Breast09 trial, Enhertu (trastuzumab deruxtecan) combined with pertuzumab was evaluated as a first-line treatment for HER2-positive metastatic breast cancer, compared to a standard regimen of a taxane, trastuzumab, and pertuzumab (THP). Topline data were shared in indicated that the Enhertu combination reduced the risk of disease progression or death by 44%. Median progression-free survival (PFS) reached 40.7 months with the Enhertu regimen versus 26.9 months for THP, a benefit observed across patient subgroups. Investigator-assessed median PFS was 40.7 months for the Enhertu arm and 20.7 months for THP. The confirmed objective response rate was 85.1% for the Enhertu combination and 78.6% for THP, with 58 complete responses in the Enhertu group compared to 33 with THP. The median duration of response was 39.2 months for the Enhertu combination and 26.4 months for THP. Overall survival data was not yet mature, though an early trend favored the Enhertu combination. The MATTERHORN trial assessed Imfinzi (durvalumab) with standard FLOT chemotherapy as a perioperative treatment for resectable, early-stage, and locally advanced gastric and gastroesophageal junction (GEJ) cancers, compared to chemotherapy alone. Topline data were released in March. A planned interim analysis showed that the Imfinzi-based regimen led to a 29% reduction in the risk of disease progression, recurrence, or death. Median event-free survival (EFS) was not reached in the Imfinzi arm, compared to 32.8 months in the chemotherapy-alone arm. The estimated 24-month EFS rate was 67.4% for the Imfinzi regimen and 58.5% for chemotherapy alone. A trend towards improved overall survival was noted for the Imfinzi-based regimen, with formal assessment to follow. The SERENA-6 trial investigated camizestrant combined with a cyclin-dependent kinase (CDK) 4/6 inhibitor (palbociclib, ribociclib or abemaciclib) in patients with hormone receptor (HR)-positive, HER2-negative advanced breast cancer whose tumors developed an ESR1 mutation during first-line treatment with an aromatase inhibitor (AI) and a CDK4/6 inhibitor. Topline data were shared in February. The trial compared switching to the camizestrant combination against continuing the AI plus CDK4/6 inhibitor. The camizestrant combination reduced the risk of disease progression or death by 56%. Median PFS was 16.0 months for patients who switched, versus 9.2 months for those continuing the AI combination. The median time to deterioration of global health status was 23.0 months for the camizestrant arm and 6.4 months for the AI combination arm. While data for time to second disease progression and overall survival were immature, a trend favored the camizestrant combination for PFS2. Price Action: AZN stock is trading lower by 0.95% at $72.14 at last checkMonday. Read Next:Photo by Piotr Swat Shutterstock UNLOCKED: 5 NEW TRADES EVERY WEEK. Click now to get top trade ideas daily, plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets. Get the latest stock analysis from Benzinga? ASTRAZENECA (AZN): Free Stock Analysis Report This article AstraZeneca Highlights Significant Gains Across Three Major Cancer Trials At ASCO originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved.
Economic Times
01-06-2025
- Business
- Economic Times
AstraZeneca breast cancer medicine slows disease by over six months
Agencies Camizestrant works as a hormone therapy to stop estrogen from attaching to cancer cells and helping them to grow. New York: AstraZeneca Plc's experimental breast cancer pill delayed disease progression by over six months, according to data from a new study that is likely to capture investors' attention. Camizestrant, in combination with other cancer medicines, helped patients with a specific type of breast cancer to live for a median of 16 months without their cancer progressing, compared with 9.2 months for those taking the current standard treatment. Astra hopes the study data, presented at the American Society of Clinical Oncology's annual meeting in Chicago, will help establish a new treatment strategy for some breast cancer patients. Camizestrant works as a hormone therapy to stop estrogen from attaching to cancer cells and helping them to grow. When other potential uses for camizestrant are taken into account, Astra believes the drug could bring in over $5 billion in annual sales. But analysts are more cautious as other similar drugs have failed, with Barclays estimating potential peak year sales at $3.6 billion. AstraZeneca has established itself as a cancer drug powerhouse under CEO Pascal Soriot, with medicines including Tagrisso and Imfinzi fueling growth.
Time of India
01-06-2025
- Business
- Time of India
AstraZeneca breast cancer medicine slows disease by over six months
AstraZeneca's new breast cancer pill, Camizestrant, shows promising results. The drug delayed cancer progression by over six months in trials. Camizestrant, combined with other medicines, helped patients live longer without cancer worsening. AstraZeneca hopes this data will establish a new treatment approach. The company anticipates significant sales, though analysts offer more conservative estimates. Tired of too many ads? Remove Ads New York: AstraZeneca Plc's experimental breast cancer pill delayed disease progression by over six months, according to data from a new study that is likely to capture investors' attention. Camizestrant , in combination with other cancer medicines, helped patients with a specific type of breast cancer to live for a median of 16 months without their cancer progressing, compared with 9.2 months for those taking the current standard hopes the study data, presented at the American Society of Clinical Oncology's annual meeting in Chicago, will help establish a new treatment strategy for some breast cancer works as a hormone therapy to stop estrogen from attaching to cancer cells and helping them to other potential uses for camizestrant are taken into account, Astra believes the drug could bring in over $5 billion in annual sales. But analysts are more cautious as other similar drugs have failed, with Barclays estimating potential peak year sales at $3.6 billion. AstraZeneca has established itself as a cancer drug powerhouse under CEO Pascal Soriot, with medicines including Tagrisso and Imfinzi fueling growth.
The Star
01-06-2025
- Health
- The Star
Immunotherapy drugs show major progress in early-stage cancer
SOUTH-EAST ASIA (Bloomberg): Drugs that boost the body's immune system to fight disease are showing promise in treating a variety of cancers in earlier stages, a development primed to expand their use and transform care for stubborn diseases like gastric and colon cancer. Immunotherapy treatments such as Opdivo from Bristol Myers Squibb Co., Imfinzi from AstraZeneca PLC, and Roche Holding AG's Tecentriq have become bestsellers by increasing survival times in a number of advanced cancers. Now the treatments are showing success against early and mid-stage cancers, according to results of large trials being presented at the American Society of Clinical Oncology meeting in Chicago this weekend. One highlight is that the drugs are preventing recurrences in operable tumors that are at high risk of relapsing. "We're learning that immunotherapy may, in fact, be more effective when you have less of a tumor burden,' said Jean Bourhis, an oncologist at Lausanne University Hospital in Switzerland, who led a study on patients with squamous cell carcinoma of the head and neck. "The key is using it earlier.' Treatment for that kind of head and neck cancer hasn't fundamentally changed in two decades. Use of Bristol's Opdivo in the study slashed the recurrence rate by nearly a quarter after three years when used after surgery to help prevent a relapse. This development could impact about 40% of people diagnosed with the disease, Bourhis said. In a study sponsored by AstraZeneca, researchers found that using the firm's Imfinzi drug before and after surgery reduced the odds by 29% over a two-year period that a nasty type of operable gastric or gastroesophageal junction cancer would relapse or progress. The development sets the stage for a new global standard of care for such cancers, which are particularly common in Asia, doctors said. Significantly Bolstered In a study on colon cancer, sponsored by the National Cancer Institute, oncologists found that adding Roche's Tecentriq to standard chemotherapy used after surgery significantly bolstered the number of patients who were alive and disease free after three years. The finding represents a major advance in the field, the study's lead investigator said, and could help roughly 15% of patients with operable colon cancer that has spread to the lymph nodes. "We have a real potential to cure many of these patients,' the investigator, Mayo Clinic oncologist Frank Sinicrope, said in an interview. For the companies, expanding the use of immune drugs to earlier stage cancers may provide a new source of revenue to an aging group of blockbusters. "This brings a commercial opportunity,' said Susan Galbraith, AstraZeneca's executive vice president for oncology research. The company has discussed with regulators the potential for the drug to get approved for the new use case, she said, declining to go into detail of where those talks stood. Merck & Co.'s immunotherapy Keytruda, which is featured in multiple studies at ASCO, shows how lucrative treating disease early can be. It has become the world's best-selling medicine thanks in part to its use in early cancer. Of the drug's 41 approved uses, nine are now for early-stage disease. Treating cancer early is "where our growth is,' Dean Li, head of research at Merck, said Thursday at an investor conference. "But it's not just economic growth. This is where you can cure patients.' Upending Medicine New immunotherapy results in head and neck cancer are poised to upend decades of medical practice. For patients with an aggressive form of head and neck cancer, the longstanding first-line treatment was to surgically remove the tumor and use chemotherapy and radiation to keep the disease at bay. The Opdivo study showed that adding the drug to the standard of care cut the risk of cancer recurrence three years after treatment by 24%. That finding comes on the heels of a successful head and neck study from Merck's rival Keytruda drug. In a big study presented in April, Keytruda reduced the risk of relapse when it was used both before and after surgery in head and neck patients. That potential new use is now under review by US regulators. In AstraZeneca's study being presented at ASCO, using Imfinzi before and after surgery was able to increase the number of people alive without a recurrence or disease progression after two years to 67.4% from 58.5%. "For patients facing a high risk of relapse, this brings new hope for long-term survival,' said Yelena Y. Janjigian, an oncologist at New York's Memorial Sloan Kettering Cancer Center, who was lead investigator on the study. "It is a pretty big deal.' Will Murray, a 52-year-old retired New York police detective, discovered he had a tumor at the junction of his esophagus and stomach in April 2022. It was operable, but he was at high risk of relapse. In an interview, he said the high death rate from this type of cancer terrified him. But Murray received one of the last spots in the AstraZeneca study and got into the immunotherapy arm. His tumor started shrinking even before the surgery. And since the operation, it hasn't come back, although he did suffer thyroid deficiency, a side effect of immune therapy drugs. Murray now has to eat carefully and can't sleep flat due to the stomach operation, but he can mostly live a normal life, including taking long walks and going on trips with his girlfriend. He credits the immunotherapy treatment trial for helping keep his tumors at bay. "It saved my life,' Murray said. --With assistance from Danielle Chaves. -- ©2025 Bloomberg L.P.
Mint
01-06-2025
- Health
- Mint
Immunotherapy Drugs Show Major Progress in Early-Stage Cancer
(Bloomberg) -- Drugs that boost the body's immune system to fight disease are showing promise in treating a variety of cancers in earlier stages, a development primed to expand their use and transform care for stubborn diseases like gastric and colon cancer. Immunotherapy treatments such as Opdivo from Bristol Myers Squibb Co., Imfinzi from AstraZeneca PLC, and Roche Holding AG's Tecentriq have become bestsellers by increasing survival times in a number of advanced cancers. Now the treatments are showing success against early and mid-stage cancers, according to results of large trials being presented at the American Society of Clinical Oncology meeting in Chicago this weekend. One highlight is that the drugs are preventing recurrences in operable tumors that are at high risk of relapsing. 'We're learning that immunotherapy may, in fact, be more effective when you have less of a tumor burden,' said Jean Bourhis, an oncologist at Lausanne University Hospital in Switzerland, who led a study on patients with squamous cell carcinoma of the head and neck. 'The key is using it earlier.' Treatment for that kind of head and neck cancer hasn't fundamentally changed in two decades. Use of Bristol's Opdivo in the study slashed the recurrence rate by nearly a quarter after three years when used after surgery to help prevent a relapse. This development could impact about 40% of people diagnosed with the disease, Bourhis said. In a study sponsored by AstraZeneca, researchers found that using the firm's Imfinzi drug before and after surgery reduced the odds by 29% over a two-year period that a nasty type of operable gastric or gastroesophageal junction cancer would relapse or progress. The development sets the stage for a new global standard of care for such cancers, which are particularly common in Asia, doctors said. In a study on colon cancer, sponsored by the National Cancer Institute, oncologists found that adding Roche's Tecentriq to standard chemotherapy used after surgery significantly bolstered the number of patients who were alive and disease free after three years. The finding represents a major advance in the field, the study's lead investigator said, and could help roughly 15% of patients with operable colon cancer that has spread to the lymph nodes. 'We have a real potential to cure many of these patients,' the investigator, Mayo Clinic oncologist Frank Sinicrope, said in an interview. For the companies, expanding the use of immune drugs to earlier stage cancers may provide a new source of revenue to an aging group of blockbusters. 'This brings a commercial opportunity,' said Susan Galbraith, AstraZeneca's executive vice president for oncology research. The company has discussed with regulators the potential for the drug to get approved for the new use case, she said, declining to go into detail of where those talks stood. Merck & Co.'s immunotherapy Keytruda, which is featured in multiple studies at ASCO, shows how lucrative treating disease early can be. It has become the world's best-selling medicine thanks in part to its use in early cancer. Of the drug's 41 approved uses, nine are now for early-stage disease. Treating cancer early is 'where our growth is,' Dean Li, head of research at Merck, said Thursday at an investor conference. 'But it's not just economic growth. This is where you can cure patients.' New immunotherapy results in head and neck cancer are poised to upend decades of medical practice. For patients with an aggressive form of head and neck cancer, the longstanding first-line treatment was to surgically remove the tumor and use chemotherapy and radiation to keep the disease at bay. The Opdivo study showed that adding the drug to the standard of care cut the risk of cancer recurrence three years after treatment by 24%. That finding comes on the heels of a successful head and neck study from Merck's rival Keytruda drug. In a big study presented in April, Keytruda reduced the risk of relapse when it was used both before and after surgery in head and neck patients. That potential new use is now under review by US regulators. In AstraZeneca's study being presented at ASCO, using Imfinzi before and after surgery was able to increase the number of people alive without a recurrence or disease progression after two years to 67.4% from 58.5%. 'For patients facing a high risk of relapse, this brings new hope for long-term survival,' said Yelena Y. Janjigian, an oncologist at New York's Memorial Sloan Kettering Cancer Center, who was lead investigator on the study. 'It is a pretty big deal.' Will Murray, a 52-year-old retired New York police detective, discovered he had a tumor at the junction of his esophagus and stomach in April 2022. It was operable, but he was at high risk of relapse. In an interview, he said the high death rate from this type of cancer terrified him. But Murray received one of the last spots in the AstraZeneca study and got into the immunotherapy arm. His tumor started shrinking even before the surgery. And since the operation, it hasn't come back, although he did suffer thyroid deficiency, a side effect of immune therapy drugs. Murray now has to eat carefully and can't sleep flat due to the stomach operation, but he can mostly live a normal life, including taking long walks and going on trips with his girlfriend. He credits the immunotherapy treatment trial for helping keep his tumors at bay. 'It saved my life,' Murray said. --With assistance from Danielle Chaves. More stories like this are available on
